Skip to content

Corcept Therapeutics

US · CORT #1285 by market cap Listed 1970
63.62 -1.36 -2.09%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 8.35 In line with history 66th percentile
5-year average 8.04 · #453 of 511 in Biotechnology
P/E ratio 47.83 Expensive vs history 69th percentile
5-year average 58.68 · forward 11.45 · #61 of 74 in Biotechnology
P/S ratio 7.23 In line with history 54th percentile
5-year average 7.97 · forward 4.21 · #162 of 392 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Corcept Therapeutics (CORT) 6.96B 47.83 8.35 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value79.83 Economic moatNarrow UncertaintyHigh

Trading 25.5% below Morningstar's fair value estimate.

Fair value

Corcept Therapeutics Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $79.83 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth increases our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's EBITDA per share growth sits in the top 10% globally. This suggests rapid margin expansion is underway, or new markets are being tapped, which contributes to our view that shares are undervalued.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 10.5%, a core component of valuation, sits in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Corcept Therapeutics discussion 0 comments

Add a comment